Gastroenterology
Zollinger-Ellison Syndrome
5
Pipeline Programs↗
0
Active Trials↗
4
Companies Involved↗
Zollinger-Ellison Syndrome is an early-stage landscape with 5 programs across 4 companies. The most active players are Sanofi, AstraZeneca, Dexcel Pharma Technologies Ltd.. 3 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Phase 31
Analysis
Trial Status
4
clinical trials
Completed4 · 100%
Clinical Trials
Trial Activity
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00001165·999 enrolled
Treatment of Zollinger-Ellison Syndrome With Prevacid
Completed·—·Phase 4·NCT00204373·72 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)